(PR NEWSWIRE) DJ: Bradley Pharmaceuticals Anticipates Significant Sales In
DJ: Bradley Pharmaceuticals Anticipates Significant Sales Increases for Lubrin
Vaginal Moisturizer as a Result of the Popularity of Viagra
FAIRFIELD, N.J.--(BUSINESS WIRE)--May 7, 1998--BRADLEY PHARMACEUTICALS, INC.
(NASDAQ NM: BPRX) foresees male Viagra(R) (Registered trademark of Pfizer,
Inc. NYSE: PFE) patients increased sexual drive significantly affecting
female usage of Lubrin(R) Vaginal Lubricant inserts. It is estimated in
excess of 20 million post-menopausal women currently suffer from vaginal
dryness.
Many health-care experts share the view of Karin Martin, Sex Therapist at
Hillside Hospital's Sexuality Center in Lake Success, New York, who spoke
about male patients in their mid 40's through 60's taking Viagra(R) and
"their partners are happy they are able to have a more complete sexual
relationship." Many other experts including Glenda Carle, author of "Don't
Bet on the Prince!", state that a number of women who have gone through
menopause may have to use additional vaginal lubricants.
Bradley Pharmaceuticals' reports increased sales for Lubrin(R) since the
introduction of Viagra(R) and expects sales to increase more with increased
sexual activity among middle-aged Viagra(R) users and their partners.
Lubrin(R) is a leading vaginal lubricant specifically designed to provide
fast and prolonged lubrication for vaginal dryness. It has been recommended
for years by Obstetricians and Gynecologists as a proven, safe and reliable
form of personal lubrication which is odorless, colorless and non-staining.
Lubrin(R) which simulates the body's natural lubrication, is designed to be
the most convenient, non-messy vaginal lubricant available.
Lubrin(R), available without a prescription, is distributed nationally and
available in independent pharmacies as well as pharmacy chains such as:
Walgreens, CVS and Eckerds.
BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products
and over-the-counter pharmaceuticals and health-related products throughout
the United States as well as in twenty-six international markets.
This release may contain forward-looking statements which reflect
management's current views of future events and operations. These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action, capital requirements
and competing products. Any changes in such assumptions are external factors
and could produce significantly different results.
CONTACT: Bradley Pharmaceuticals, Inc.
Daniel Glassman
Chairman and CEO
973/882-1505, Ext. 210
or
DeMonte Associates
Cynthia DeMonte
212/473-3700
e-mail: cdemonte@aol.com
*** end of story *** |
